Tourette Syndrome Clinical Trial
Official title:
Understanding the Anatomy and Physiology of the Sensory Experience and Its Role in Generating Tics in Tourette Syndrome
Verified date | October 25, 2016 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will investigate the sensation that many people with Tourette syndrome (TS)
experience before they have a motor tic. It will also test whether blocking the sensation
causes the tic to stop.
People between 18 and 65 years of age with TS who have at least once tic involving an arm may
be eligible for this 3-part study. Those enrolled may participate in all parts or in part 1
or part 2. Those who choose to participate in part 3 must first complete part 2. All must
stop taking medication for TS and any other medication that may affect the brain for at least
1 week before the study.
Part 1
After numbing the skin or muscles of the arm or leg where a pre-tic sensation is experienced,
the response of the nerves will be tested by asking subjects to rate the strength of the
sensation after a pinprick and by stimulating the nerves with small electrical shocks. Then,
over the course of approximately one hour, subjects will report pre-tic sensations while
their motor tics are counted. The onset of each tic will be identified with EMG, a test using
electrodes on the skin to indicate the activity of the muscles.
Part 2
Subjects brain waves are recorded using magnetoencephalography (MEG) while they are
experiencing tics andpre-tic sensory experiences. MEG is a test that records magnetic field
changes produced by brain activity. Subjects sit in a chair under a dome containing magnetic
field detectors. They watch a clock and report the time a sensory experience starts. Tics are
recorded with EMG. Later, a standard MRI of the brain (scan using a magnetic field and radio
waves) is done to see which parts of the brain produced the activity recorded with MEG.
Part 3
Repetitive transcranial magnetic stimulation (rTMS) is used to try to stop the pre-tic
sensations. For TMS, the subject sits in a chair. A wire coil is held on the subject s scalp,
and a brief electrical current is passed through the coil, creating a magnetic pulse that
stimulates a region of the brain. The goal of this stimulation is to reduce the sensory
experience that precedes a tic in one region of the body. During stimulation, the subject
hears a click and may feel a pulling sensation on the skin under the coil. There may be a
twitch in the muscles of the face, arm or leg. This study uses a pattern of repeated pulses
delivered in short bursts. Following each train of pulses, the effect of the stimulation on
sensation will be tested by asking the subject to rate the strength of a pinprick and of a
vibration. In addition, the nerves are stimulated with small shocks to evaluate the effect of
the TMS on nerve activity. To determine the effect of TMS on the pre-tic sensation, subjects
are asked to watch a clock and report when they are having a sensory experience. The effect
on motor tics will be evaluated by using EMG to indicate the tics.
Status | Completed |
Enrollment | 54 |
Est. completion date | October 25, 2016 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
- INCLUSION CRITERIA: Tourette subjects must be 18-65 years of age of any race, gender, or handedness. They must be able to sit for at least 2 hours and remain at the testing site for up to 8 hours. They must be able to follow instructions and participate in reporting sensory experiences. The upper extremity tic to be studied must occur at least once a minute, but no more frequently than once every 5 seconds. Individuals with comorbid attention deficit disorder (ADD or ADHD) or with obsessive-compulsive disorder (OCD) will not be excluded. Healthy volunteers must be 18-65 years of age, of any race, gender, or handedness. EXCLUSION CRITERIA: 1. Inability to stop taking all central-acting medications, including those used to treat tics, for at least one week prior to the study 2. Current use of coumadin, heparin, or lovenox 3. Any additional movement disorder, including tremor, myoclonus, or dystonia 4. A diagnosis of major depression or bipolar disorder 5. Frequent or severe headaches 6. Any history of or current experience of hallucinations 7. Any history of a seizure or epilepsy or a family history of epilespy 8. Any prior brain injury, brain tumor or other lesion, stroke, or surgery 9. A diagnosis of increased intracranial pressure 10. A history of significant heart disease 11. Any history of hearing problems, or abnormal results on auditory testing (part I or II) 12. Any of the following: pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pump, or shrapnel fragments (part I and II only) 13. Any history of work as a welder or metal worker (part I and II) 14. Current pregnancy 15. Tobacco use (cigarette, chewing, or other) in the month prior to the study (part II) 16. Diagnosis of, treatment for, or self-report of alcohol abuse (alcoholism) (part I) 17. Cocaine use in the year prior to involvement in the study (part I) 18. Use of any medication within one month prior to the study with cholinergic or anticholinergic properties, including (but not limited to): nicotine patch, nicorette gum, atrovent, enablex, toriaz, ditropan, vesicare, detrol, sanctura, artane, Aricept, cogentin, akineton, zanaflex, norflex, flexeril, lomotil, mototen, levsin, razadyne, exelon (part I) 19. Peripheral neuropathy or carpal tunnel syndrome (part I) 20. Inability to hold head still for 10 minutes (part I). |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Alary F, Simões C, Jousmäki V, Forss N, Hari R. Cortical activation associated with passive movements of the human index finger: an MEG study. Neuroimage. 2002 Mar;15(3):691-6. — View Citation
Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005 Oct;26(5):785-93. Epub 2005 Jul 5. Review. — View Citation
Banaschewski T, Woerner W, Rothenberger A. Premonitory sensory phenomena and suppressibility of tics in Tourette syndrome: developmental aspects in children and adolescents. Dev Med Child Neurol. 2003 Oct;45(10):700-3. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Inhibition of the sensory experience frequency and intensity. | |||
Secondary | The relationship between inhibition of sensory and motor experiences; and detecting and localizing an electromagnetic signal corresponding to the sensory experience. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04851678 -
Longitudinal Impact of Stressors in Adults With Tourette Syndrome
|
||
Completed |
NCT02605902 -
Trial to Demonstrate the Efficacy and Safety of Internet-delivered Behavioral Treatment for Adults With Tic Disorders
|
N/A | |
Completed |
NCT04007913 -
Incorporating teleCBIT Into a Hospital-Based Tic Program
|
N/A | |
Completed |
NCT02900144 -
Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)
|
N/A | |
Completed |
NCT02216474 -
Brain Stimulation in Movement Disorders
|
N/A | |
Completed |
NCT02256475 -
Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome
|
Phase 1 | |
Completed |
NCT01329198 -
Brain Stimulation for the Treatment of Tourette Syndrome
|
N/A | |
Terminated |
NCT00952601 -
Pilot Study of the Modified Atkins Diet for Tourette Syndrome
|
Phase 1 | |
Enrolling by invitation |
NCT00355927 -
Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.
|
N/A | |
Completed |
NCT00206323 -
A Randomized, Placebo-controlled, Tourette Syndrome Study.
|
Phase 3 | |
Completed |
NCT00004376 -
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
|
Phase 3 | |
Completed |
NCT04498364 -
Extinction Learning in Adults With Tourette Syndrome
|
N/A | |
Completed |
NCT03325010 -
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Completed |
NCT01702077 -
Neurofeedback for Tourette Syndrome
|
N/A | |
Completed |
NCT01719523 -
Open-Trial of EPI-743 for Adults With Tourette Syndrome
|
Phase 1 | |
Completed |
NCT00231985 -
Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
|
Phase 2 | |
Completed |
NCT00206336 -
An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
|
Phase 3 | |
Terminated |
NCT03732534 -
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
|
Phase 2 | |
Completed |
NCT03625453 -
Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder
|
Phase 2 |